# Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II

> **NCT06882499** · NA · NOT_YET_RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 74 (estimated)

## Conditions studied

- Breast Cancer, Metastatic
- Metastatic Breast Cancer

## Interventions

- **RADIATION:** Stereotactic Ablative Radiotherapy
- **OTHER:** Physician's choice of systemic treatment

## Key facts

- **NCT ID:** NCT06882499
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2032-06
- **Final completion:** 2032-06
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06882499

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06882499, "Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06882499. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*